Loading market dashboard
AI/ML Innovations Inc.
AIMLFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Appointments bring more than 50 combined years of cardiac monitoring, ECG overread (the expert clinical review of ECG recordings by trained technicians and cardiologists), and regulatory validation experience to NeuralCloud's clinical and operational leadership team. Leadership additions strengthen AI/ML's clinical-governance and operational readiness as it advances its neural-network ECG signal-processing technology through regulatory review toward potential future commercialization.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / May 11, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "Offering") pursuant to which the Company has issued convertible debentures ("Debentures") in the aggregate principal amount of $1,917,500. Together with the first tranche closing, the Company has issued Debentures in the aggregate principal amount of $2,867,500.
Founding Architect of Canadian Cardiac Electrophysiology and 45-Year Authority on Electrocardiography Joins AIML's Medical Advisory Board TORONTO, ON / ACCESS Newswire / May 11, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Martin Stephen Green, MD, FRCPC, Professor Emeritus at the University of Ottawa, to the Company's Medical Advisory Board (the "MAB"), effective April 27, 2026. Dr. Green joins the MAB at the invitation of Dr. Paul Dorian, MD, MSc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / April 24, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has completed its previously announced share for debt issuance with certain service providers of the Company pursuant to which the Company has issued an aggregate of 17,118,420 common shares (the "Subject Shares") at a deemed price of Cdn$0.05 per Subject Share totalling Cdn$855,921 in consideration of past services and satisfaction of outstanding indebtedness (the "Debt Settlement"). The Subject Shares are subject to a statutory hold period expiring on August 25, 2026.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / April 17, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has completed its previously announced share for debt issuance with certain service providers of the Company pursuant to which the Company has issued an aggregate of 17,118,420 common shares (the "Subject Shares") at a deemed price of Cdn$0.05 per Subject Share in consideration of past services and satisfaction of outstanding indebtedness. The Subject Shares are subject to a statutory hold period expiring on August 18, 2026.
Collaboration Expands Reach of MaxYield™ into Remote Heart Monitoring and Preventive Cardiology Applications TORONTO, ON / ACCESS Newswire / March 31, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) today announced that its wholly owned subsidiary, Neural Cloud Solutions Inc. ("Neural Cloud"), entered into a reseller agreement on March 25th, 2026 with a European-based digital health platform specializing in cloud-based ECG and heart rate variability (HRV) analytics. Under the agreement, the partner platform will integrate and resell Neural Cloud's MaxYield™ ECG signal-processing technology to its customers as either a standalone capability or as part of a bundled remote cardiac monitoring solution.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / March 27, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement (the "Offering") pursuant to which the Company has issued convertible debentures ("Debentures") in the aggregate principal amount of $950,000. The Debentures may be converted into units of the Company ("Units") at the option of the holder of the Debentures at any time at a conversion price of $0.05 per Unit, with each Unit being comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant").
Agreement expands NeuralCloud's role in cardiovascular research and academic collaborations MaxYield™ platform to support heart rate variability analysis in post-exertional malaise research TORONTO, ON / ACCESS Newswire / March 25, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that on March 18th, 2026 the Company entered into a research services agreement with Dr. Kegan Moneghetti, MBBS (Hons) FRACP FCSANZ PhD, of the Baker Heart and Diabetes Institute, to provide AI-powered ECG signal processing in support of an ongoing cardiovascular research study. Under the agreement, NeuralCloud will apply its proprietary MaxYield™ ECG processing platform to existing ECG recordings supplied by the research team.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / March 12, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it is proposing to complete a non-brokered private placement (the "Offering") pursuant to which the Company will issue convertible debentures ("Debentures") in the principal amount of up to $3,000,000. The Debentures may be converted into units of the Company ("Units") at the option of the holder of the Debentures at any time at a conversion price of $0.05 per Unit, with each Unit being comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant").
